{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:34:16Z","timestamp":1788986056343,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The current endocarditis management strategies among Tennessee healthcare facilities for people who inject drugs (PWID) were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a survey-based study of healthcare facilities that treat infective endocarditis in PWID within Tennessee. The primary outcome of the study was to describe current practice among facilities regarding the treatment of endocarditis in PWID, including approaches to addiction management, antimicrobial therapy, and cardiac surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 17 facilities that responded to the survey but only 16 facilities completed the entire survey. Although 15 facilities (88%) responded that they evaluate patients for substance use disorders on admission, only 4 (24%) of those facilities offered addiction consultation service. Regarding antibiotic therapy, most facilities offered completion of intravenous antibiotic course inpatient or at a skilled nursing facility (94% and 75%, respectively). Other treatment options less commonly offered by facilities included: transition to oral antibiotics (56%), use of long-acting lipoglycopeptides (50%), and outpatient parenteral antibiotic therapy (25%). Of the 16 facilities that completed the survey, only 7 performed cardiac surgery and 6 performed catheter-based interventions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although most facilities surveyed offered completion of antibiotic therapy either as inpatient or at a skill nursing facility, they were less likely to offer alternative options such as home infusion antibiotics, long-acting antibiotics, or oral antibiotic treatment for endocarditis. Most facilities screened for substance abuse on admission, but few provided addiction services. There may be an opportunity to enhance care for PWID through alternative antibiotic therapies and addiction services.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf150","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:38:29Z","timestamp":1743392309000},"source":"Crossref","is-referenced-by-count":2,"title":["Trends in the Management of Infective Endocarditis for Patients Who Inject Drugs: A Survey of Healthcare Facilities in Tennessee"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5205-693X","authenticated-orcid":false,"given":"Jarett","family":"Worden","sequence":"first","affiliation":[{"name":"Pharmacy Practice, Belmont University College of Pharmacy & Health Sciences , Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulonda","family":"Warren","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, Belmont University College of Pharmacy & Health Sciences , Nashville, Tennessee, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"2025052712090002700_ofaf150-B1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2025052712090002700_ofaf150-B2","doi-asserted-by":"crossref","first-page":"e031589","DOI":"10.1161\/JAHA.123.031589","article-title":"Trends in infective endocarditis mortality in the United States: 1999 to 2020: a cause for alarm","volume":"12","author":"Chobufo","year":"2023","journal-title":"JAHA"},{"key":"2025052712090002700_ofaf150-B3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2025052712090002700_ofaf150-B4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jss.2022.10.004","article-title":"Association of intravenous drug use and length of stay following infective endocarditis","volume":"282","author":"Nodoushani","year":"2023","journal-title":"J Surg Res"},{"key":"2025052712090002700_ofaf150-B5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.mayocp.2019.08.023","article-title":"Clinical and economic burden of hospitalizations for infective endocarditis in the United States","volume":"95","author":"Alkhouli","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2025052712090002700_ofaf150-B6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3201\/eid2603.191408","article-title":"Methicillin-resistant staphylococcus aureus bloodstream infections and injection drug use, Tennessee, USA, 2015\u20132017","volume":"26","author":"Parikh","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2025052712090002700_ofaf150-B7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025052712090002700_ofaf150-B8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.15585\/mmwr.mm6722a2","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs\u2014six sites, 2005\u20132016","volume":"67","author":"Jackson","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"14","key":"2025052712090002700_ofaf150-B9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/CIR.0000000000001090","article-title":"Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association","volume":"146","author":"Baddour","year":"2022","journal-title":"Circulation"},{"key":"2025052712090002700_ofaf150-B10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025052712090002700_ofaf150-B11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/cid\/ciab367","article-title":"Comparative 1-year outcomes of invasive staphylococcus aureus infections among persons with and without drug use: an observational cohort study","volume":"74","author":"Appa","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025052712090002700_ofaf150-B12","doi-asserted-by":"crossref","first-page":"ofy194","DOI":"10.1093\/ofid\/ofy194","article-title":"Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature","volume":"5","author":"Suzuki","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"Supplement_5","key":"2025052712090002700_ofaf150-B13","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1093\/infdis\/jiaa025","article-title":"Feasibility and safety of outpatient parenteral antimicrobial therapy in conjunction with addiction treatment for people who inject drugs","volume":"222","author":"Price","year":"2020","journal-title":"J Infect Dis"},{"key":"2025052712090002700_ofaf150-B14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/cid\/ciz654","article-title":"Outpatient parenteral antimicrobial therapy plus buprenorphine for opioid use disorder and severe injection-related infections","volume":"70","author":"Fanucchi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025052712090002700_ofaf150-B15","first-page":"1","article-title":"Design and protocol of the Buprenorphine plus Outpatient Parenteral Antimicrobial Therapy (B-OPAT) study: a randomized clinical trial of integrated outpatient treatment of opioid use disorder and severe, injection-related infections","volume":"9","author":"Fanucchi","year":"2022","journal-title":"Ther Adv Infect Dis"},{"key":"2025052712090002700_ofaf150-B16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jhm.2597","article-title":"Successful implementation of outpatient parenteral antimicrobial therapy at a medical respite facility for homeless patients","volume":"11","author":"Beieler","year":"2016","journal-title":"J Hosp Med"},{"key":"2025052712090002700_ofaf150-B17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/ADM.0b013e318294b1eb","article-title":"Residential addiction treatment for injection drug users requiring intravenous antibiotics: a cost-reduction strategy","volume":"7","author":"Jewell","year":"2013","journal-title":"J Addict Med"},{"key":"2025052712090002700_ofaf150-B18","doi-asserted-by":"crossref","first-page":"106069","DOI":"10.1016\/j.ijantimicag.2020.106069","article-title":"Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review","volume":"56","author":"Thomas","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025052712090002700_ofaf150-B19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka","year":"2020","journal-title":"Antibiotics"},{"key":"2025052712090002700_ofaf150-B20","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive gram-positive infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025052712090002700_ofaf150-B21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2025052712090002700_ofaf150-B22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025052712090002700_ofaf150-B23","author":"Turner"},{"key":"2025052712090002700_ofaf150-B24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S. aureus bacteremia (dots): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"key":"2025052712090002700_ofaf150-B25","doi-asserted-by":"crossref","first-page":"100937","DOI":"10.1016\/j.lanepe.2024.100937","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) global 2024","volume":"42","author":"Mar\u00edn-Hernandez","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025052712090002700_ofaf150-B26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052712090002700_ofaf150-B27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciad119","article-title":"Real-world application of oral therapy for infective endocarditis: a multicenter, retrospective, cohort study","volume":"77","author":"Freling","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025052712090002700_ofaf150-B28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/cid\/ciac714","article-title":"Outcomes of partial oral antibiotic treatment for complicated staphylococcus aureus bacteremia in people who inject drugs","volume":"76","author":"Wildenthal","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025052712090002700_ofaf150-B29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIR.0000000000000923","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"2025052712090002700_ofaf150-B30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.amjmed.2015.09.024","article-title":"Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis","volume":"129","author":"Rosenthal","year":"2016","journal-title":"Am J Med"},{"key":"2025052712090002700_ofaf150-B31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/M18-2124","article-title":"Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data","volume":"170","author":"Schranz","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025052712090002700_ofaf150-B32","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/eurheartj\/ehab898","article-title":"Current recommendations and uncertainties for surgical treatment of infective endocarditis: a comparison of American and European cardiovascular guidelines","volume":"43","author":"Wang","year":"2022","journal-title":"Eur Heart J"},{"key":"2025052712090002700_ofaf150-B33","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jtcvs.2016.09.093","article-title":"2016 the American Association for Thoracic Surgery (AATS) consensus guidelines: surgical treatment of infective endocarditis: executive summary","volume":"153","author":"Pettersson","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025052712090002700_ofaf150-B34"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf150\/62847034\/ofaf150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf150\/62847034\/ofaf150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf150\/62847034\/ofaf150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:09:52Z","timestamp":1748362192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf150\/8104500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf150","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"ofaf150"}}